Idera Pharmaceuticals Announces Preliminary Data From Phase 2a Clinical Study Of IMO-2055 Monotherapy In Renal Cell Carcinoma

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced preliminary data from the first part of a Phase 2 clinical study conducted by the Company of IMO-2055 monotherapy in patients with metastatic or recurrent clear cell renal carcinoma (RCC). The primary objective was not achieved in the study. The primary objective was tumor response based on RECIST (Response Evaluation Criteria In Solid Tumors). Secondary objectives included time to progression, survival and safety.

More: continued here

Comments are closed.



My RX Pharmacy - Buy Online: My RX pharmacy
Order Anti Depressants - Buy Online: Order Anti Depressants
RX Pills Shop - Buy Drugs: RX pills shop
RX Discount Plus - Buy Drugs: Discount plus - A method that you get extra money even if you take discount products.
RX Pharmacy Online - Buy Drugs: RX Pharmacy Online
Your Health Rx - : Your Health Rx
Medicine Value - Medicine Value: Value the medicine advice
Latest News...